In our study, we concluded that serum IGF-1 and EGF levels in patients with Parkinson’s disease were associated with neuropsychiatric and cognitive function, but we admit that these associations, as well as those of IGF-1 and EGF with nonmotor symptoms, need to be further validated for the following main reasons. This evidence concerns the gene IGF1 and Parkinson disease.